There are currently 603 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
BlueWind RENOVA iStim™ System for the Treatment of OAB
Recruiting
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Gender:
Female
Ages:
Between 18 years and 80 years
Trial Updated:
12/29/2023
Locations: Adult Pediatric Urology & Urogynecology, Omaha, Nebraska
Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)
Exoskeleton Footwear to Improve Walking
Recruiting
The purpose of this study is to determine the best assistance level of an exoskeleton footwear (EF) that can assist walking for people older than 40 with and without peripheral artery disease (PAD). The test will be performed on two different groups of people for this study that include: 1) people with PAD, and 2) individuals who don't have PAD. Data will be collected from 50 healthy older individuals and 25 patients with PAD, both groups will be 40 years or older. Gait biomechanics, muscle ox... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
12/29/2023
Locations: Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha, Nebraska
Conditions: Peripheral Arterial Disease
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: Nebraska Methodist Hospital, Omaha, Nebraska
Conditions: Endometrial Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
Recruiting
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Recruiting
The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: Progression-free and overall survival of patients receiving this combination; Quality of Life (QOL); and Tumor response on imaging The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). Th... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
12/20/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Glioma, Glioblastoma Multiforme
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Recruiting
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocar... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
REal-World Analyses of Stroke - Thrombus Occlusion REtrieval
Recruiting
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.
Gender:
All
Ages:
All
Trial Updated:
12/15/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Acute Ischemic Stroke, Stroke, Ischemic, Vessel Occlusion
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Prospective Study of Pregnancy in Women With Cystic Fibrosis
Recruiting
In this study, the investigators aim to evaluate changes in lung function in women with cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure to highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Gender:
Female
Ages:
16 years and above
Trial Updated:
12/12/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Pregnancy Related, Cystic Fibrosis
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
Recruiting
The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: 1 Site, Omaha, Nebraska
Conditions: Alopecia Areata
A Registry for People With T-cell Lymphoma
Recruiting
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Gender:
All
Ages:
All
Trial Updated:
12/06/2023
Locations: University of Nebraska (Data collection only), Omaha, Nebraska
Conditions: T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
Recruiting
Chronic graft-versus-host disease (cGvHD) is one of the most serious complications following BMT (Bone Marrow Transplantation). cGvHD occurs when donor immune cells "attack" the tissues and organs of the person receiving the BMT. cGvHD can be difficult to treat once it is established leading to poor quality of life for recipients of a BMT. The goal of this study is to determine if, by using biomarkers, the investigators can predict which patients are at the highest risk of developing cGvHD after... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/02/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder